Dr. Rini on Axitinib for Treatment of Metastatic Renal Cell Carcinoma

Brian I. Rini, MD
Published: Monday, Oct 19, 2015



Brian Rini, MD, associate professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, discusses a phase Il study that examined axitinib as a frontline therapy for metastatic renal cell carcinoma (mRCC).

The randomized dose titration study enrolled approximately 200 patients with mRCC. Patients were first treated with the standard dose at 5 mg twice daily for 30 days. Criteria to be randomized to receive an increased dosage included a lack of incidence of toxicity and/or hypertension.

Patients were then randomized to an increased dose of axitinib versus placebo, which was the standard dose. A 20% advantage in response rate was demonstrated in the titration arm. Progression-free survival and overall survival was favored in the titration arm, but was not found to be statistically significant. Researchers determined that dose titration needs to be carefully done so as to not harm patients with higher levels of toxicities.
 


Brian Rini, MD, associate professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, discusses a phase Il study that examined axitinib as a frontline therapy for metastatic renal cell carcinoma (mRCC).

The randomized dose titration study enrolled approximately 200 patients with mRCC. Patients were first treated with the standard dose at 5 mg twice daily for 30 days. Criteria to be randomized to receive an increased dosage included a lack of incidence of toxicity and/or hypertension.

Patients were then randomized to an increased dose of axitinib versus placebo, which was the standard dose. A 20% advantage in response rate was demonstrated in the titration arm. Progression-free survival and overall survival was favored in the titration arm, but was not found to be statistically significant. Researchers determined that dose titration needs to be carefully done so as to not harm patients with higher levels of toxicities.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x